Table 2.
Endpoint | Rate (95% CI, %) |
---|---|
16-Week PFS rate | 42.1 (27.9-57.8) |
Objective response rate | 12.5 (5.0-28.1) |
Disease control rate | 59.4 (42.4-76.4) |
PSA response rate | 12.9 (1.3-25.4) |
CI, confidence interval; PFS, progression-free survival; PSA, prostate specific antigen.